Kiniksa Pharmaceuticals, Ltd.

KNSA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$183,581$107,954$122,715$122,470
Short-Term Investments$60,046$98,417$67,893$59,731
Receivables$41,724$21,266$20,316$3,985
Inventory$26,364$31,122$21,599$3,675
Other Curr. Assets$20,084$17,538$10,537$6,585
Total Curr. Assets$331,799$276,297$243,060$196,446
Property Plant & Equip (Net)$11,038$12,665$7,043$8,384
Goodwill$0$0$0$0
Intangibles$16,250$17,250$18,250$19,250
Long-Term Investments$0$0$0$0
Tax Assets$211,151$219,283$185,495$0
Other NC Assets$10,315$827$5,824$8,720
Total NC Assets$248,754$250,025$216,612$36,354
Other Assets$0$0$0$0
Total Assets$580,553$526,322$459,672$232,800
Liabilities
Payables$2,039$8,246$7,899$1,868
Short-Term Debt$1,993$2,253$3,301$3,381
Tax Payable$0$0$0$0
Deferred Revenue$0$307$0$0
Other Curr. Liab.$96,589$52,860$35,866$39,575
Total Curr. Liab.$100,621$63,666$47,066$44,824
LT Debt$7,862$10,005$2,618$2,669
Deferred Rev, NC$31,811$11,954$12,000$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$1,823$1,858$1,839$270
Total NC Liab.$41,496$23,817$16,457$2,939
Other Liabilities$0$0$0$0
Cap. Leases$9,855$12,258$5,919$6,050
Total Liabilities$142,117$87,483$63,523$47,763
Equity
Pref Stock$0$0$0$0
Common Stock$20$20$19$18
Retained Earnings-$521,143-$477,950-$492,034-$675,397
AOCI-$163$6$44-$66
Other Equity$959,722$916,763$888,120$860,482
Total Equity$438,436$438,839$396,149$185,037
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$580,553$526,322$459,672$232,800
Net Debt-$173,726-$95,696-$116,796-$116,420